Octopus Ventures

Octopus Ventures is one of Europe’s largest and most active early-stage venture firms, deploying over £200 million annually across health, fintech, deep tech, consumer, and B2B software. Operating from London and New York with a network of partners across the US and Asia, Octopus is part of the broader Octopus Group, a UK-headquartered investment platform that manages over £13 billion across venture, energy, real estate, and wealth. The firm’s health team has been investing in digital health, biotech, and consumer health for over a decade and has built one of the more credible cross-border franchises connecting UK and European founders with US scale-up capital.

Will Gibbs, who joined Octopus in 2013 and serves on the firm’s health team, is the public face of the practice and writes a meaningful share of its healthcare checks. Gibbs has explored adjacent and sometimes-taboo health categories, with investments in substance addiction (QuitGenius), LGBTQ+ sexual health, consumer health (Skin and Me), and biotech (Ori Biotech). He spent a year based in Octopus’s New York office in 2016 and continues to support portfolio companies expanding into the US, where he has co-invested alongside SoftBank, Kinnevik, Atomico, and EQT Partners. The broader health team includes partners and principals with operating backgrounds at digital health companies, consumer health brands, and life sciences, and the firm has expanded its biotech bench in recent years.

Octopus typically writes initial checks of £1 million to £10 million at seed and Series A, with the capacity to lead and to follow on into Series B. The firm is one of the most active seed and Series A investors in UK and European digital health and is willing to back founders earlier in their journey than most US-headquartered firms. For US deals, Octopus generally co-invests rather than leads, partnering with specialist healthcare investors. Geographic scope is UK, continental Europe, and the US, with the strongest network density in London, Berlin, Paris, and New York. The firm increasingly supports cross-border companies whose founding teams are in Europe but who will scale primarily in the US.

Founders who should approach Octopus are UK and European founders building digital health, consumer health, biotech, and care delivery companies with global ambitions. The firm is particularly well suited for founders who want a UK or European lead at seed or Series A and who plan to expand into the US in subsequent rounds. Octopus is also a credible partner for biotech founders building in the UK, particularly those at the intersection of cell and gene therapy manufacturing, computational biology, and platform engineering. Founders building therapeutics-only companies that require US specialist capital from the start, or pure US healthcare services companies without a European angle, should consider US-headquartered firms first. Founders building B2B SaaS for healthcare without a clinical wedge can also pitch Octopus’s broader B2B team.

Entry path runs through warm introductions from portfolio CEOs, fellow European VCs (including Index, Atomico, and Balderton), and the broader London and New York operator networks. Gibbs is publicly active on LinkedIn and at HLTH, ViVE, and London-based digital health conferences. Cold inbound through the Octopus website is triaged and converts at moderate rates with a strong UK or European founder story and clear commercial traction. Diligence is partner-driven and typically runs three to six weeks for competitive deals.

In a pitch, lead with the founder market fit, the customer wedge, and the unit economics. Gibbs and the health team think in terms of building European health champions that can compete globally, and they want to see ambition that extends beyond a UK or European exit. Bring a clear plan for international expansion, including the US market, and a credible commercial narrative that does not rely solely on NHS or single-payer dynamics. The firm’s added value is most powerful for founders who use the broader Octopus Group network: corporate advisory, the firm’s connections to NHS and European public-sector healthcare buyers, and the cross-Atlantic introductions that Octopus partners can make to US specialist co-investors. Founders building from Europe with global ambition will find Octopus one of the most strategically useful tier-one partners across the digital health and biotech categories.